Challenges with Fixing the Ceiling Price Under the 2013
Soon after the implementation of the 2013 DPCO, some industry observers argued that the ceiling prices set by the NPPA were much higher relative to those resulting from a cost-based pricing...
Zydus challenges ceiling prices for 8 formulations, DoP rejects review
In yet another stern stance on implementing the new pharmaceutical pricing policy, the Department of Pharmaceuticals (DoP) has rejected the review petitions by Zydus Healthcare which challenged the price fixation done by the National Pharmaceutical Pricing Authority (NPPA) in case of its eight formulations.
DoP asks NPPA to seek clarification & final authentic data from IMS on
The Department of Pharmaceuticals (DoP) has directed the National Pharmaceutical Pricing Authority (NPPA) to seek further clarification and final authentic data from IMS for the scheduled medicine ciprofloxacin hydrochloride drop 0.30% to revisit the ceiling price fixed by the NPPA. The NPPA vide price fixation Order S.O. No.1017(E) dated 2.4.
Re-fixing ceiling prices: NPPA asks pharma companies to submit sales
The NPPA works under the DOP. Initiating the process of re-fixing the ceiling prices of eight essential drugs, the National Pharmaceutical Pricing Authority (NPPA) has asked various pharmaceutical companies, which are involved in their production and sales, to submit their sales and pricing data.
DoP asks companies to revise MRP of drugs on which GST rates have been
The Department of Pharmaceuticals (DoP) has directed all the manufacturers and marketing companies to revise the maximum retail price (MRP) of drugs or formulations on which Goods and Services Tax (GST) has been reduced taking into effect the revised rates of GST.
